-
-
-
-
-
-
-
Oncolytics reports positive preclinical data for pelareorep-RAS combo
-
-
-
-
-
-
-
Oncolytics shifts focus to anal, colorectal cancer studies
-
-
-
-
-
-
-
Oncolytics Biotech gets FDA alignment on pancreatic cancer drug trial
-
-
-
-
-
-
-
Oncolytics Biotech shareholders elect eight directors at annual meeting
-
-
-
-
-
-
-
Oncolytics Biotech (ONCY) Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer
-
-
-
-
-
-
-
Oncolytics Biotech (ONCY) Reports Favorable Results for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling Study
-
-
-
-
-
466,180 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

